常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.81/-0.91
|
|
企业价值
93.65M
|
| 资产负债 |
|
每股账面净值
1.28
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
26.03M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 08:59 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |

2.12 
